Doganay Goksel, Khodr Bereha, Georgiou George, Khalil Zeinab
Department Medicine, University of Melbourne, Victoria 3010, Australia.
Curr Alzheimer Res. 2006 Apr;3(2):137-45. doi: 10.2174/156720506776383086.
The amyloid-beta (Abeta) peptide has been linked to the pathology of Alzheimer's disease (AD). There is now evidence to support a vasoconstrictive effect of Abeta protein that could be detected in peripheral skin microvasculature. In this study we investigated the ability of acetylcholinesterase (AChE) inhibitors, Donepezil and Rivastigmine, to modulate the vasoconstrictor activity of Abeta25-35 and Abeta1-40. The ability of these drugs to improve endothelial mediated vascular responses to acetylcholine and bradykinin subsequent to perfusion of Abeta peptides was also investigated. The vascular responses to Abeta peptides, acetylcholine, bradykinin and sodium nitroprusside and their modulation by acetylcholinesterase inhibitors were examined in the base of a vacuum induced blister raised on the rat hind footpad using laser Doppler flowmetry. Abeta25-35 (1 microM) and Abeta1-40 (0.1 microM) induced a vasoconstrictor effect and significantly reduced the vasodilator response to acetylcholine (100 microM) and bradykinin (1 microM). Donepezil (100 microM) and Rivastigmine (100 microM) both reduced the vasoconstrictor effect of Abeta peptides, and significantly restored the endothelial vascular response to acetylcholine. Similarly, Donepezil significantly restored the endothelial vascular response to bradykinin. The results also showed that the actions of acetylcholinesterase inhibitors are independent of a direct action on smooth muscle cell reactivity or on endothelial cell function in the absence of Abeta. The current study provides the first evidence in vivo to suggest that acetylcholinesterase inhibitors modulate the vasoconstrictive effects of Abeta peptides at the level of skin microvasculature. We raise the notion that Donepezil and Rivastigmine mediate these vascular modulatory effects via an action on Abeta-mediated vasoconstrictor mechanisms rather than an independent action on endothelial or smooth muscle cell mediated responses.
β-淀粉样蛋白(Aβ)肽与阿尔茨海默病(AD)的病理过程相关。目前有证据支持Aβ蛋白的血管收缩作用,这一作用可在外周皮肤微血管系统中检测到。在本研究中,我们调查了乙酰胆碱酯酶(AChE)抑制剂多奈哌齐和卡巴拉汀调节Aβ25-35和Aβ1-40血管收缩活性的能力。还研究了在灌注Aβ肽后,这些药物改善内皮介导的血管对乙酰胆碱和缓激肽反应的能力。使用激光多普勒血流仪在大鼠后足垫上通过真空诱导形成的水疱底部,检测了血管对Aβ肽、乙酰胆碱、缓激肽和硝普钠的反应以及乙酰胆碱酯酶抑制剂对它们的调节作用。Aβ25-35(1微摩尔)和Aβ1-40(0.1微摩尔)诱导血管收缩作用,并显著降低对乙酰胆碱(100微摩尔)和缓激肽(1微摩尔)的血管舒张反应。多奈哌齐(100微摩尔)和卡巴拉汀(100微摩尔)均降低了Aβ肽的血管收缩作用,并显著恢复了内皮对乙酰胆碱的血管反应。同样,多奈哌齐显著恢复了内皮对缓激肽的血管反应。结果还表明,在没有Aβ的情况下,乙酰胆碱酯酶抑制剂的作用独立于对平滑肌细胞反应性或内皮细胞功能的直接作用。本研究提供了体内首个证据,表明乙酰胆碱酯酶抑制剂在皮肤微血管水平调节Aβ肽的血管收缩作用。我们提出这样的观点,即多奈哌齐和卡巴拉汀通过作用于Aβ介导的血管收缩机制来介导这些血管调节作用,而不是独立作用于内皮或平滑肌细胞介导的反应。